Chevy Chase Trust Holdings LLC Has $39.39 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Chevy Chase Trust Holdings LLC lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 1.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 239,219 shares of the company's stock after selling 2,644 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Zoetis worth $39,387,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Mission Wealth Management LP lifted its holdings in shares of Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after buying an additional 59 shares in the last quarter. HUB Investment Partners LLC raised its stake in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC raised its stake in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after purchasing an additional 64 shares in the last quarter. Lindbrook Capital LLC grew its position in shares of Zoetis by 1.8% during the 4th quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock worth $595,000 after purchasing an additional 65 shares in the last quarter. Finally, Ironwood Investment Management LLC increased its holdings in shares of Zoetis by 0.8% during the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock worth $1,361,000 after purchasing an additional 68 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE:ZTS opened at $157.76 on Wednesday. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The stock's 50-day simple moving average is $159.89 and its 200 day simple moving average is $163.06. The firm has a market capitalization of $70.23 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 2.61 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $1.38 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis's payout ratio is presently 35.91%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. UBS Group cut their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Finally, Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and a consensus price target of $212.13.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.